The role of T regulatory cells in human sepsis

Journal of Autoimmunity

Volumn 32, Issue 3-4, 2009, Pages 211-215

  Kessel, Aharon ^a   Bamberger, Ellen ^a   Masalha, Muhamad ^a   Toubi, Elias ^a  

^a BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

Foxp3; Sepsis; T regulatory cells; TGF

Indexed keywords

ANTIINFECTIVE AGENT; CD25 ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CELL INTERACTION; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE FUNCTION; LYMPHOCYTE TRANSFER; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SEPSIS; SEPTIC SHOCK;

ANIMALS; ANTIGENS, CD; CYTOKINES; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; SEPSIS; SHOCK, SEPTIC; T-LYMPHOCYTES, REGULATORY;

EID: 67349103355     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2009.02.014     Document Type: Article

References (53)

1. Bone R.C., Balk R.A., Cerra F.B., Dellinger R.P., Fein A.M., Knaus W.A., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101 (1992) 1644-1655
2. Warren H.S. Strategies for the treatment of sepsis. N Engl J Med 336 (1997) 952-953
3. Stone R. Search for sepsis drugs goes on despite past failures. Science 264 (1994) 365-367
4. Lederer J.A., Rodrick M.L., and Mannick J.A. The effects of injury on the adaptive immune response. Shock 11 (1999) 153-159
5. Oberholzer A., Oberholzer C., and Moldawer L.L. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 16 (2001) 83-96
6. Hotchkiss R.S., and Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 348 (2003) 138-150
7. Munford R.S., and Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 163 (2001) 316-321
8. American College of Chest Physicians/Society of Critical Care Medicine consensus conference committee Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874.
9. Kox W.J., Volk T., Kox S.N., and Volk H.D. Immunomodulatory therapies in sepsis. Intensive Care Med 26 (2000) S124-S128
10. Hoyt D.B., Ozkan A.N., Ninnemann J.L., Hansbrough J.F., Pinney E., and Wormsley S. Trauma peptide induction of lymphocyte changes predictive of sepsis. J Surg Res 45 (1988) 342-348
11. Lin R.Y., Astiz M.E., Saxon J.C., and Rackow E.C. Altered leukocyte immunophenotypes in septic shock. Studies of HLA-DR, CD11b, CD14, and IL-2R expression. Chest 104 (1993) 847-853
12. Nishijima M.K., Takezawa J., Hosotsubo K.K., Takahashi H., Shimada Y., and Yoshiya I. Serial changes in cellular immunity of septic patients with multiple organ system failure. Crit Care Med 14 (1986) 87-91
13. Hotchkiss R.S., Tinsley K.W., Swanson P.E., Schmieg Jr. R.E., Hui J.J., Chang K.C., et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 166 11 (2001) 6952-6963
14. Papathanassoglou E.D., Moynihan J.A., McDermott M.P., and Ackerman M.H. Expression of Fas (CD95) and Fas ligand on peripheral blood mononuclear cells in critical illness and association with multiorgan dysfunction severity and survival. Crit Care Med 29 4 (2001) 709-718
15. Döcke W.D., Randow F., Syrbe U., Krausch D., Asadullah K., Reinke P., et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 3 (1997) 678-681
16. Shevach E.M. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2 (2002) 389-400
17. Sonoda K., Exley M., Snapper S., Balk S.P., and Stein-Streilein J. CD-1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J Exp Med 190 (1999) 1215-1225
18. Zedler S., Biol D., Bone R.C., Baue A.E., Donnersmarck G.H.V., and Faist E. T-cell reactivity and its predictive role in immunosuppression after burns. Crit Care Med 27 (1999) 66-72
19. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., and Toda M. Immunologic self-tolerance by activated T cells expressing IL-2 receptor α chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155 (1995) 1151-1164
20. Mills K.H. Regulatory T cells: friend or foe in immunity to infection?. Nat Rev Immunol 4 (2004) 841-855
21. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22 (2004) 531-562
22. Jiang H., and Chess L. An integrated view of suppressor T cell subsets in immunoregulation. J Clin Invest 114 (2004) 1198-1208
23. Piccirillo C.A., and Thornton A.M. Cornerstone of peripheral tolerance: naturally occurring CD4+CD25+ regulatory T cells. Trends Immunol 25 (2004) 374-380
24. Gavin M.A., Rasmussen J.P., Fontenot J.D., Vasta V., Manganiello V.C., Beavo J.A., et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445 (2007) 771-775
25. Lin W., Haribhai D., Relland L.M., Truong N., Carlson M.R., Williams C.B., et al. Regulatory T cell development in the absence of functional Foxp3. Nat Immunol 8 (2007) 359-368
26. Williams L.M., and Rudensky A.Y. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 8 (2007) 277-284
27. Campbell D.J., and Ziegler S.F. FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nat Rev Immunol 7 (2007) 305-310
28. Shimizu J., Yamazaki S., Takahashi T., Ishida Y., and Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3 (2002) 135-142
29. Takahashi T., Tagami T., Yamazaki S., Uede T., Shimizu J., Sakaguchi N., et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192 2 (2000) 303-310
30. Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T., Miyara M., Fehervari Z., et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322 5899 (2008) 271-275
31. Liu W., Putnam A.L., Xu-Yu Z., Szot G.L., Lee M.R., Zhu S., et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Treg cells. J Exp Med 203 (2006) 1701-1711
32. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 203 (2006) 1693-1700
33. Belkaid Y., and Rouse B.T. Natural regulatory T cells in infectious disease. Nat Immunol 6 (2005) 353-360
34. Monneret G., Debard A.L., Venet F., Bohe J., Hequet O., Bienvenu J., et al. Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit Care Med 31 (2003) 2068-2071
35. Venet F., Pachot A., Debard A.L., Bohé J., Bienvenu J., Lepape A., et al. Increased percentage of CD4+CD25+ regulatory T cells during septic shock is due to the decrease of CD4+CD25- lymphocytes. Crit Care Med 32 (2004) 2329-2331
36. Venet F., Chung C.S., Kherouf H., Geeraert A., Malcus C., Poitevin F., et al. Increased circulating regulatory T cells (CD4+CD25+CD127-) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med (2008) [Epub ahead of print]
37. Saito K., Wagatsuma T., Toyama H., Ejima Y., Hoshi K., Shibusawa M., et al. Sepsis is characterized by the increases in percentages of circulating CD4+CD25+ regulatory T cells and plasma levels of soluble CD25. Tohoku J Exp Med 216 1 (2008) 61-68
38. Decker D., Tolba R., Springer W., Lauschke H., Hirner A., and von Ruecker A. Abdominal surgical interventions: local and systemic consequences for the immune system-a prospective study on elective gastrointestinal surgery. J Surg Res 126 (2005) 12-18
39. Heidenreich S., Schmidt M., August C., Cullen P., Rademaekers A., and Pauels H.G. Regulation of human monocyte apoptosis by the CD14 molecule. J Immunol 159 (1997) 3178-3188
40. Heidenreich S. Monocyte CD14: a multifunctional receptor engaged in apoptosis from both sides. J Leukoc Biol 65 (1999) 737-743
41. Taams L.S., van Amelsfort J.M., Tiemessen M.M., Jacobs K.M., de Jong E.C., Akbar A.N., et al. Modulation of monocyte/macrophage function by human CD4+CD25+ regulatory T cells. Hum Immunol 66 (2005) 222-230
42. Venet F., Pachot A., Debard A.L., Bohe J., Bienvenu J., Lepape A., et al. Human CD4+CD25+ regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-dependent mechanism. J Immunol 177 (2006) 6540-6547
43. Perlman H., Pagliari L.J., Nguyen N., Bradley K., Liu H., and Pope R.M. The Fas-FasL death receptor and PI3K pathways independently regulate monocyte homeostasis. Eur J Immunol 31 (2001) 2421-2430
44. Brown N.J., Hutcheson J., Bickel E., Scatizzi J.C., Albee L.D., Haines G.K., et al. Fas death receptor signaling represses monocyte numbers and macrophage activation in vivo. J Immunol 173 (2004) 7584-7593
45. Kiener P.A., Davis P.M., Starling G.C., Mehlin C., Klebanoff S.J., Ledbetter J.A., et al. Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. J Exp Med 185 (1997) 1511-1516
46. Lewkowicz P., Lewkowicz N., Sasiak A., and Tchórzewski H. Lipopolysaccharide-activated CD4+CD25+ T regulatory cells inhibit neutrophil function and promote their apoptosis and death. J Immunol 177 (2006) 7155-7163
47. Sabroe I., Prince L.R., Jones E.C., Horsburgh M.J., Foster S.J., Vogel S.N., et al. Selective roles for Toll-like receptor (TLR)2 and TLR4 in the regulation of neutrophil activation and life span. J Immunol 170 (2003) 5268-5275
48. Francois S., Benna J.E., Dang P.M.C., Pedruzzi E., Gougerot-Pocidalo M.A., and Elbim C. Inhibition of neutrophil apoptosis by TLR agonists in whole blood: involvement of the phosphoinositide 3-kinase/Akt and NF-κB signaling pathways, leading to increased levels of Mcl-1, A1, and phosphorylated Bad. J Immunol 174 (2005) 3633-3642
49. Wisnoski N., Chung C.S., Chen Y., Huang X., and Ayala A. The contribution of CD4+CD25+ T-regulatory-cells to immune suppression in sepsis. Shock 27 (2007) 251-257
50. Scumpia P.O., Delano M.J., Kelly K.M., O'Malley K.A., Efron P.A., McAuliffe P.F., et al. Increased natural CD4+CD25+ regulatory T cells and their suppressor activity do not contribute to mortality in murine polymicrobial sepsis. J Immunol 177 (2006) 7943-7949
51. Chen X., Bäumel M., Männel D.N., Howard O.M., and Oppenheim J.J. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol 179 (2007) 154-161
52. Heuer J.G., Zhang T., Zhao J., Ding C., Cramer M., Justen K.L., et al. Adoptive transfer of in vitro-stimulated CD4+CD25+ regulatory T cells increases bacterial clearance and improves survival in polymicrobial sepsis. J Immunol 174 (2005) 7141-7146
53. Scumpia P.O., Delano M.J., Kelly-Scumpia K.M., Weinstein J.S., Wynn J.L., Winfield R.D., et al. Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis. Blood 110 10 (2007) 3673-3681